UNSPSC 51201817: Pidotimod

This classification denotes an immunostimulant with the molecular formula C9H12N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 785363R681, chemically known as 4-thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))- but generally known as pidotimod, which bears US NIH Compound Identifier 65944. European Medicines Agency schedules Pidotimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09826MIG.

UNSPSC 51201817 Pidotimod, a Commodity code, does not align with state and local procurement activity recently posted under this designation. The sole recent opportunity tagged to the code is the Mississippi State Department of Health's sole source notice for Yellow Fever Vaccine from Sanofi Pasteur, posted July 13, 2026, with an objection deadline of August 3, 2026 — a vaccine procurement unrelated to pidotimod, an immunostimulant pharmaceutical used in respiratory and urinary tract infection treatment. The mismatch suggests either miscoding in the state procurement database or a narrow niche where pidotimod procurement under this UNSPSC number does not generate regular state and local solicitation activity.

No additional recent opportunities appear in the record. The code shows insufficient activity to characterize issuing-body mix, geographic concentration, or representative procurement patterns at the state and local level.